Otenabant
Clinical data | |
---|---|
ATC code | none |
Identifiers | |
| |
CAS Number | 686344-29-6 Y |
PubChem (CID) | 10052040 |
ChemSpider | 8227602 N |
UNII | J8211Y53EF N |
KEGG | D09362 Y |
ChEMBL | CHEMBL562668 N |
Chemical and physical data | |
Formula | C25H25Cl2N7O |
Molar mass | 510.4 g/mol |
3D model (Jmol) | Interactive image |
| |
| |
NY (what is this?) (verify) |
Otenabant (CP-945,598) is a drug which acts as a potent and highly selective CB1 antagonist.[1] It was developed by Pfizer for the treatment of obesity,[2] but development for this application has been discontinued following the problems seen during clinical use of the similar drug rimonabant.[3]
See also
References
- ↑ Kim, M.; et al. (2008), "Design, chemical synthesis, and biological evaluation of novel triazolyl analogues of taranabant (MK-0364), a cannabinoid-1 receptor inverse agonist" (PDF), Tetrahedron, 64 (48): 10802–10809, doi:10.1016/j.tet.2008.09.057
- ↑ Woods SC. The endocannabinoid system: novel pathway for cardiometabolic Risk-factor reduction. Journal of the American Academy of Physician Assistants. 2007 Nov;Suppl Endocannabinoid:7-10. PMID 18047036
- ↑ http://www.pfizer.com
Phytocannabinoids |
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Endocannabinoids |
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Synthetic cannabinoids |
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Allosteric CBR ligands |
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Endocannabinoid enhancers (inactivation inhibitors) |
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Anticannabinoids (antagonists/inverse agonists/antibodies) |
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Receptor (ligands) |
| ||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Transporter (modulators) |
| ||||||||||||||||||
Enzyme (modulators) |
| ||||||||||||||||||
Others |
| ||||||||||||||||||
|
This article is issued from Wikipedia - version of the 4/2/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.